Clinical Report: Efficacy of Transcatheter Closure of Patent Foramen Ovale in Migraine Patients

Overview

This study demonstrates that transcatheter closure of patent foramen ovale (PFO) is highly effective in reducing migraine symptoms in Chinese patients, with an overall responder rate of 83.98%. Younger patients and more recent procedural experience are significant predictors of treatment success.

Background

Migraine is a common neurological disorder that significantly impacts quality of life. The association between PFO and migraine, particularly in patients with aura, has prompted investigations into PFO closure as a potential treatment. Understanding the efficacy and safety of this intervention is crucial for optimizing migraine management strategies.

Data Highlights

Key Findings

• Transcatheter PFO closure resulted in an 83.98% overall migraine responder rate.
• Younger patients (15-24 years) had a significantly higher responder rate (89.67%) compared to older patients (45-54 years, 80.66%).
• More recent procedural years were associated with higher success rates (OR = 0.89 per half-year delay).
• The procedure had a 100% technical success rate with only 3.49% minor complications.
• Therapeutic benefits were sustained after discontinuation of dual antiplatelet therapy, with an 81.93% responder rate at >12 months.

Clinical Implications

The findings suggest that transcatheter PFO closure may be a viable treatment option for selected migraine patients, particularly younger individuals. Clinicians should consider procedural experience as a factor influencing outcomes when recommending this intervention.

Conclusion

Transcatheter PFO closure is a promising and safe treatment for migraine in Chinese patients, with sustained benefits observed post-procedure. Further studies are needed to refine patient selection criteria.

Related Resources & Content

1. Frontiers in Neurology, 2026 -- PFO closure in ischemic stroke: insights from a single-center real-world cohort
2. Pediatric Cardiology, 2024 -- Recent Advances in Understanding Patent Foramen Ovale in Pediatric Patients
3. Clinical Research in Cardiology, 2023 -- Incidence of New Atrial Fibrillation Following Percutaneous Closure of Patent Foramen Ovale: A Meta-Analytic Review
4. SCAI Guidelines for the Management of Patent Foramen Ovale - PMC
5. Neurology, 2024 -- A Prospective, Multicenter, Randomized, Double Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Patent Foramen Ovale Closure with the STARFlex Septal Repair Implant to Prevent Refractory Migraine Headaches: the MIST Trial
6. Administration of full cangrelor dosage for the immediate management of small ruptured cerebral aneurysms using flow diverters: insights from a single institution study
7. SCAI Guidelines for the Management of Patent Foramen Ovale - PMC
8. A Prospective, Multicenter, Randomized, Double Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Patent Foramen Ovale Closure with the STARFlex Septal Repair Implant to Prevent Refractory Migraine Headaches: the MIST Trial | Neurology
9. Effect of Residual Interatrial Shunt on Migraine Burden After Transcatheter Closure of Patent Foramen Ovale | JACC: Cardiovascular Interventions